Literature DB >> 23883068

Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care.

Polychronis Pavlidis1, Fergus Jq Chedgy, Jeremy A Tibble.   

Abstract

OBJECTIVE: Assessment of faecal calprotectin (fCal) test performance in primary care within an irritable bowel syndrome (IBS) diagnostic pathway.
METHODS: Study based on consecutively collected fCal data from 962 patients, aged 18-45, presenting to their general practitioner (GP) with persistent gastrointestinal symptoms.
RESULTS: Six hundred and eighty six (71%) patients had a negative (<50 μg/g) and 276 (29%) had a positive fCal. 28% (77/276) of the patients testing positive and 3% (17/686) of those testing negative had an organic diagnosis. At 50 μg/g the sensitivity of the test for organic disease was 82%, (95% confidence interval [CI] 73-89) and the specificity was 77% (95% CI 74-80), with negative predictive value (NPV) and positive predictive value (PPV) of 98% and 28%, respectively. A cut-off increase to 150 μg/g reduces the NPV by 1% whilst increasing the PPV to 71%. This would reduce colonoscopy and flexible sigmoidoscopy bookings by 10% at the cost of four missed cases of inflammatory bowel disease.
CONCLUSIONS: This study provides the first evidence on the use of fCal testing in primary care. The low prevalence of organic disease in this setting has a significant impact on test performance. This suggests a need for change in cut-off value, to improve PPV whilst accepting a reduction in test sensitivity, if it is to be used as part of the pathway for management of patients with suspected IBS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23883068     DOI: 10.3109/00365521.2013.816771

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  26 in total

1.  Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India.

Authors:  Geir Larsson; Koticherry Thrivikrama Shenoy; Ramalingom Ramasubramanian; Lakshmikanthan Thayumanavan; Leena Kondarappassery Balakumaran; Gunnar A Bjune; Bjørn A Moum
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

Review 2.  Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.

Authors:  Anet A Soubières; Andrew Poullis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 3.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

4.  Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study.

Authors:  James Turvill; Assad Aghahoseini; Nala Sivarajasingham; Kazim Abbas; Murtaza Choudhry; Kostantinos Polyzois; Kostantinos Lasithiotakis; Dimitra Volanaki; Baek Kim; Fiona Langlands; Helen Andrew; Jesper Roos; Samantha Mellen; Daniel Turnock; Alison Jones
Journal:  Br J Gen Pract       Date:  2016-06-06       Impact factor: 5.386

5.  Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study.

Authors:  Gea A Holtman; Yvonne Lisman-van Leeuwen; Boudewijn J Kollen; Obbe F Norbruis; Johanna C Escher; Angelika Kindermann; Yolanda B de Rijke; Patrick F van Rheenen; Marjolein Y Berger
Journal:  Ann Fam Med       Date:  2016-09       Impact factor: 5.166

Review 6.  Comparing outcomes from tailored meta-analysis with outcomes from a setting specific test accuracy study using routine data of faecal calprotectin testing for inflammatory bowel disease.

Authors:  Karoline Freeman; Brian H Willis; Ronan Ryan; Sian Taylor-Phillips; Aileen Clarke
Journal:  BMC Med Res Methodol       Date:  2022-07-12       Impact factor: 4.612

Review 7.  Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy.

Authors:  Massimo Bellini; Dario Gambaccini; Cristina Stasi; Maria Teresa Urbano; Santino Marchi; Paolo Usai-Satta
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

8.  Validating biomarkers of treatable mechanisms in irritable bowel syndrome.

Authors:  M Camilleri; A Shin; I Busciglio; P Carlson; A Acosta; A E Bharucha; D Burton; J Lamsam; A Lueke; L J Donato; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2014-09-22       Impact factor: 3.598

Review 9.  Disease monitoring in inflammatory bowel disease.

Authors:  Shannon Chang; Lisa Malter; David Hudesman
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

10.  Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway.

Authors:  James Turvill; Daniel Turnock; Hayden Holmes; Alison Jones; Eleanor Mclaughlan; Victoria Hilton; Stacey Marriott
Journal:  Frontline Gastroenterol       Date:  2018-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.